文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

现代患者队列中新诊断脑转移瘤接受 upfront 放射外科治疗患者预后评分的综合总结与回顾性评估

Comprehensive summary and retrospective evaluation of prognostic scores for patients with newly diagnosed brain metastases treated with upfront radiosurgery in a modern patient collective.
PubMed 文献 · Radiother Oncol · 2022-04-27

该回顾性研究对2014年1月至2020年3月接受 upfront 立体定向放射外科治疗的470例新诊断脑转移瘤患者计算了12种基于临床参数的预后评分,并在310例有完整实验室数据的亚组中比较了5种附加评分。全队列中位总生存期为15.8个月(95%CI 13.4-20.1),RPA的c-index最高,GGS的部分似然最高;纳入实验室评分后EC-GPA的c-index和部分似然最高;仅基于体能状态的评分表现也相当高。作者认为含实验室参数的近期评分预测性能令人信服,但仅依赖临床参数的旧评分仍有效且更易计算,仅基于体能状态的评分不显著劣于其他评分,至少应评估用于知情决策。

要点

  • 全队列中位OS为15.8个月(95%CI 13.4-20.1),所有12种预后评分均能较好区分不同预后组。
  • 总队列中RPA的c-index最高,GGS的部分似然最高;纳入实验室评分后EC-GPA的c-index和部分似然最高。
  • 仅基于体能状态的3级或4级评分表现相当高,作者认为不显著劣于其他评分,至少应评估用于知情决策。

核心结论

  • 含实验室参数的近期预后评分在预测总生存方面表现令人信服,但仅依赖临床参数的旧评分仍有效且更易计算,总体性能几乎相当。
  • 仅基于体能状态的评分不显著劣于其他评分,至少应评估用于知情决策。

研究设计与样本

  • 回顾性评估2014年1月至2020年3月接受 upfront 立体定向放射外科治疗的470例新诊断脑转移瘤患者。
  • 对470例计算12种仅基于临床参数的预后评分;在310例有完整实验室数据的亚组中比较5种附加预后评分。
  • 采用限制性平均生存时间(RMST)、部分似然和c-index作为性能评价指标,并用单变量和多变量分析识别OS预后因素。

主要发现

  • 全队列中位OS为15.8个月(95%CI 13.4-20.1)。
  • 所有预后评分均能较好地将患者分为不同预后组。
  • 总队列中RPA的c-index最高,GGS的部分似然最高。
  • 纳入实验室评分后,近期提出的EC-GPA的c-index和部分似然最高。
  • 仅基于体能状态的3级或4级评分表现相当高。

关键数值与推荐

  • 全队列中位OS为15.8个月(95%CI 13.4-20.1)。
  • 总队列中RPA的c-index最高,GGS的部分似然最高。
  • 纳入实验室评分后EC-GPA的c-index和部分似然最高。

临床怎么用

  • 作者认为,尽管含实验室参数的近期预后评分预测总生存表现令人信服,仅依赖临床参数的旧评分仍有效且更易计算,总体性能几乎相当。
  • 作者认为,仅基于体能状态的评分不显著劣于其他评分,至少应评估用于知情决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous prognostic scores (PS) for patients with brain metastases (BM) have been developed. Recently, PS based on laboratory parameters were introduced to better predict overall survival (OS). A comprehensive comparison of the wide range of scores in a modern patient collective is still missing. MATERIALS AND METHODS: Twelve PS considering clinical parameters only at the time of BM diagnosis were calculated for 470 patients receiving upfront SRS between January 2014 and March 2020. In a subcohort of 310 patients where a full laboratory dataset was available five additional prognostic scores were compared. Restricted mean survival time (RMST), partial likelihood and c-index were calculated as metrics for performance evaluation. Univariable and multivariable analysis were used to identify prognostic factors for OS. RESULTS: The median OS of the whole cohort was 15.8 months (95% C.I.: 13.4-20.1). All prognostic scores performed well in separating patients into different prognostic groups. RPA achieved the highest c-index, whereas GGS achieved highest partial likelihood with evaluation in the total cohort. With incorporation of the laboratory scores the recently suggested EC-GPA achieved highest c-index and highest partial likelihood. A prognostic score solely based on the assessment of performance status achieved considerable high performance as either 3- or 4-tiered score. Multivariable analysis revealed performance status, systemic disease status and laboratory parameters to be significantly associated with OS among variates included in prognostic scores. CONCLUSION: Although recent PS incorporating laboratory parameters show convincing performance in predicting overall survival, older scores relying on clinical parameters only are still valid and appealing as they are easier to calculate, and as overall performance is almost equal. Moreover, a score just based on performance status is not significantly inferior and should at least be assessed for informed decision making.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kraft J, van Timmeren JE, Frei S, et al. Comprehensive summary and retrospective evaluation of prognostic scores for patients with newly diagnosed brain metastases treated with upfront radiosurgery in a modern patient collective. Radiother Oncol. 2022. PMID: 35489445. doi:10.1016/j.radonc.2022.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。